Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers.

DNA- and modified virus Ankara (MVA)-vectored candidate vaccines expressing human immunodeficiency virus type 1 (HIV-1) clade A-derived p24/p17 gag fused to a string of HLA class I epitopes, called HIVA, were tested in phase I trials in healthy, HIV-1/2-uninfected adults in Oxford, United Kingdom. E...

ver descrição completa

Detalhes bibliográficos
Main Authors:	Cebere, I, Dorrell, L, Mcshane, H, Simmons, A, McCormack, S, Schmidt, C, Smith, C, Brooks, M, Roberts, J, Darwin, S, Fast, P, Conlon, C, Rowland-Jones, S, Mcmichael, A, Hanke, T
Formato:	Journal article
Idioma:	English
Publicado em:	2006

Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers.

Registos relacionados